Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Bal Pharma Ltd Performance

Today's Low
97.90
arrowIcon
Today's High
99.85
52 Wk Low
80.85
arrowIcon
52 Wk High
132.45


Open

99

Traded Value (Cr)

4.03 L

Prev. Close

99.5

VWAP

99.6

Volume

15,632

Face Value

10

Bal Pharma Ltd Fundamentals

Market Cap
₹ 160 Cr
P/E Ratio (TTM)
45.56
P/B Ratio
2.53
Debt to Equity
2.23
ROE
5.07 %
EPS (TTM)
2.23
Dividend Yield
0.98%
Book Value
40.10

Click here to know more about Fundamentals

Bal Pharma Ltd Financials

Bal Pharma Ltd Financials

Bal Pharma Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 51.23 % 51.23 % 51.61 % 51.61 %
Retail 32.15 % 32.63 % 32.19 % 32.00 %
Others 16.49 % 16.00 % 16.06 % 16.23 %
FII 0.13 % 0.13 % 0.14 % 0.17 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

51.23%

Retail

32.15%

Others

16.49%

FII

0.13%

Mutual Funds

0.00%

Promoters

51.23%

Retail

32.63%

Others

16.00%

FII

0.13%

Mutual Funds

0.00%

Promoters

51.61%

Retail

32.19%

Others

16.06%

FII

0.14%

Mutual Funds

0.00%

Promoters

51.61%

Retail

32.00%

Others

16.23%

FII

0.17%

Mutual Funds

0.00%

Resistance and Support

₹100.53

PIVOT

resistance-arrow
Resistance
First Resistance₹104.017
Second Resistance₹106.583
Third Resistance₹110.067
support-arrow
Support
First Resistance₹97.967
Second Resistance₹94.483
Third Resistance₹91.917
RSI48.828
MACD-0.238
ADX7.928
CCI-41.806

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day15,63210,96370.13
Week15,92010,93169.48
1 Month15,33210,38071.34
6 Months26,93318,01466.88

About Bal Pharma Ltd

Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May '87. In Mar.'90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations. BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations. During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The company's product range has been expanded with the introduction of AZIWIN, CAFIMOL & CORTIDERM. The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium - M, Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named 'SERVETUS' has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market during 2002. The commercial production of Formulation Plant in Uttarakhand started from 1st January, 2009. The Company floated Lifezen Healthcare Pvt Ltd during the year 2014-15 as its subsidiary. It ventured into heath care sector through its subsidiary i.e. Balance Clinics LLP. In 2016-17, it commenced its project on construction of an fully integrated API unit with an annual production capacity of 270 metric tonnes of assorted API products including Gliclazide, Ebastine, Amiloride HCL, Benzydamine HCL, Pregablin etc, located at Gauribidanur near Bangalore with an estimated investment of Rs 45 Crores. In 2017-18, the Company acquired 100% stake and management control of Golden Drugs Private Ltd, an Udaipur, Rajasthan involved in the manufacture of bulk drugs and intermediates costing Rs 14 Crores. It earmarked Rs. 36 Cr. for setting up of an bulk drug's manufacturing unit at Yadgir District , Karnataka in year 2022-23. It launched Sitagliptin (a DPP-4 Inhibitor) in the plain form, and as a combination with Metformin under the brand names SITABEND & SITABEND-M, respectively in 2023.

Managing Director

Shailesh Siroya

Founded

1987

NSE Symbol

BALPHARMA

Bal Pharma Ltd Management

NameDesignation
Shailesh SiroyaManaging Director
C V SrinivasIndependent Director
Himesh VirupakshayaExecutive Director
H S VenkateshIndependent Director
Nicola NeeladriIndependent Director
Jatish ShethIndependent Director
Kotian Chittananda DamodarWhole-time Director
Abdul BasithCompany Sec. & Compli. Officer

Bal Pharma Ltd News

Bal Pharma declare Quarterly Result
On 28 May 2024
Bal Pharma consolidated net profit rises 56.14% in the December 2023 quarter
Sales rise 6.58% to Rs 81.66 crore
Bal Pharma to table results
On 12 February 2024
Bal Pharma to conduct EGM
On 21 December 2023
Bal Pharma consolidated net profit rises 763.64% in the September 2023 quarter
Sales rise 22.88% to Rs 92.54 crore
Bal Pharma to table results
On 8 November 2023
Bal Pharma to hold EGM
On 3 October 2023
Bal Pharma to convene AGM
On 25 September 2023
Bal Pharma consolidated net profit declines 71.43% in the June 2023 quarter
Sales rise 0.79% to Rs 70.39 crore
Bal Pharma to table results
On 11 August 2023

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,58,616 Cr
₹ 1,504.90
(0.69 %)
86.97
CIPLA₹ 1,09,708 Cr
₹ 1,386.90
(2.07 %)
33.36
DIVISLAB₹ 1,00,611 Cr
₹ 3,793.65
(0.10 %)
73.75
DRREDDY₹ 98,044 Cr
₹ 5,899.00
(0.37 %)
22.59
ZYDUSLIFE₹ 97,423 Cr
₹ 984.45
(1.68 %)
36.23

Bal Pharma Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Bal Pharma Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Bal Pharma Ltd's share price is ₹98.95 as of May 10, 2024

Bal Pharma Ltd's P/E ratio is 45.56 times as of May 10, 2024.

Bal Pharma Ltd's most recent financial reports indicate a price-to-book ratio of 2.53, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Bal Pharma Ltd's market is 161 Cr as on May 10, 2024.

The current financial records of Bal Pharma Ltd show a 5.07% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Bal Pharma Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Bal Pharma Ltd's 52-week high and low as of May 10, 2024 are ₹99.85 and ₹97.9 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Bal Pharma Ltd stands at 51.23%. During the same period, Institutional Investors have shown a slight values are equal in their holdings, values are equal from 0.13% to 0.13%.